The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pre-emptive monitoring of scheduled chemotherapy reduced toxicity without diminishing efficacy in patients (pts) over age75 with gynecologic (GC) or lung cancer (LC) treated with paclitaxel and carboplatin (PC).
K. Belfihadj
No relevant relationships to disclose
H. Aboudagga
No relevant relationships to disclose
E. Fabre
No relevant relationships to disclose
F. Scotte
No relevant relationships to disclose
J. Fouque
No relevant relationships to disclose
B. Bonan
No relevant relationships to disclose
S. Oudard
No relevant relationships to disclose
O. Saint-Jean
No relevant relationships to disclose
J. Medioni
No relevant relationships to disclose